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SUMMARY The incidence and prevalence of premalignant and 
malignant skin lesions including squamous cell carcinoma (SCC) 
of the skin are increasing worldwide. The aim of the study was 
to determine TP53, Bcl-2 and growth hormone receptor (GHR) 
expression in SCC and to investigate relative importance of 
these proto-oncogenes in its biological behavior. Expression of 
TP53, Bcl-2 and GHR was determined by immunohistochemistry 
in 27 SCC specimens and adjacent perilesional skin. The 
relative proportion of immunoreactive cells was counted with 
semiquantitative method. TP53 positivity was detected in 24 
(89%), Bcl-2 in 18 (67%) and GHR in 25 (93%) of 27 SCC 
specimens investigated. In comparison with perilesional skin, 
TP53 and GHR positivity was significantly increased, and Bcl-
2 positivity significantly decreased in SCC. Increased TP53 
expression in SCC lesions implies that Tp53 mutation is an early 
and crucial event in its development. Increased GHR expression 
suggests a role of growth hormone in the development of SCC.
KEY WORDS Bcl-2; growth hormone receptor; 
immunohistochemistry; squamous cell carcinoma; TP53
INTRODUCTION
 Squamous cell carcinoma of the skin (SCC) 
is the second most common nonmelanoma skin 
cancer, frequently observed in the sun-exposed 
skin areas of the middle-aged and elderly popula-
tion (1). SCC is induced by several forms of envi-
ronmental damage, especially sun ultraviolet (UV) 
light. SCC can also arise from actinic keratosis 
(AK) (2). Furthermore, as AK shares great clini-
cal and pathological similarity with SCC, novel in-
vestigations consider AK as an initial stage in the 
development of SCC (1,3,4).
 Both AK and SCC arise from the expansion 
of keratinocyte clones with acquired mutations 
induced by UV light (4). Detailed molecular mech-
anism of SCC development and progression has 
not yet been completely elucidated. Recent lit-
erature connects AK and SCC development and 
progression with increased cell proliferation rather 
than protection from apoptosis (5,6).
 TP53 and Bcl-2 were recognized as pivotal par-
ticipants in the regulatory mechanism of Bax-medi-
ated apoptosis (6,7). Although there are relatively 
many reports on TP53 and Bcl-2 immunoreactiv-
ity in SCC, the immunopositivity detected mark-
edly varies: from 15% to 92% for TP53 (5,6,8-14) 
and from 0% to 100% for Bcl-2 (5,6,15-18). Also, 
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expression of TP53 and Bcl-2 in SCC was only 
rarely investigated simultaneously (5,6).
 Growth hormone receptor (GHR) is a novel 
proto-oncogene, which was recently detected on 
cells of various skin lesions (19,20). This finding 
implicated a role of growth hormone in the devel-
opment and progression of skin lesions. GHR ex-
pression in SCC was investigated by one author 
only (20). GHR immunopositivity of tumor cells 
was detected in all seven SCC specimens inves-
tigated but it was always weaker than in normal 
keratinocytes (20).
 Two earlier investigations done in our labora-
tory determined TP53, Bcl-2 and GHR immu-
nopositivity in two most common AK types: hyper-
trophic (HAK) and atrophic (AAK) (21,22). Current 
investigation determined immunohistochemically 
TP53, Bcl-2 and GHR expression in SCC in or-
der to evaluate their role in SCC development and 
progression. 
PATIENTS AND METHODS
 We investigated TP53, Bcl-2 and GHR expres-
sion in 27 specimens of SCC and adjacent perile-
sional skin (PS) taken from regularly sun-exposed 
skin in patients of both sexes older than 60 years 
of age. Clinical data were obtained from the files 
of the Ljudevit Jurak University Department of Pa-
thology, Sestre milosrdnice University Hospital, 
Zagreb, Croatia. Immunohistochemical determi-
nation of TP53 and Bcl-2 proteins was performed 
following the Microwave Streptavidin ImmunoPer-
oxidase (MSIP) protocol on a DAKO TechMateTM 
Horizon automated immunostainer, as described 
previously (7). The presence of GHR was dem-
onstrated by the streptavidin-biotin horseradish 
peroxidase complex (Strept ABC-HRP) technique, 
as described before (20,21). Expression of im-
munohistochemical staining was represented as 
percentage of immunoreactive cells per 1000 cells 
analyzed. The following semiquantitative evalua-
tion and scoring system were used: (-) for no im-
munoreactive tumor cells; weakly positive (+) for 
up to 10%; moderately positive (++) for 10% to 
25%; and strongly positive (+++) for more than 
25% of immunoreactive tumor cells. To estimate 
the relative importance of the study oncoproteins 
in SCC, positivity in SCC was compared with the 
level of positivity in perilesional skin. Statistical 
analysis was performed by use of χ2-test for trend 
(GraphPad InStat, version 3.05, GraphPad Soft-
ware, USA). The level of significance was set at 
p<0.05 in all cases.
RESULTS
 Expression of nuclear TP53 and cytoplasmic 
Bcl-2 and GHR proteins in perilesional skin was 
uniform: all cases examined stained weakly posi-
tive (+) for each marker. Immunopositive keratino-
cytes were mainly localized in the basal epidermal 
layer (Figure 1A, 1C and 1E). 
The majority of SCC specimens (59%) had mod-
erate to strong (++/+++) TP53 expression (Table 
1). In positive specimens most of the atypical epi-
dermal keratinocytes stained positive, while tumor 
cells in the proximity of keratin pearls remained 
negative (Figure 1B). The majority (63%) of SCC 
showed weak (+) Bcl-2 expression in sporadically 
distributed patches throughout the tumor (Figure 
1D). However, Bcl-2 protein was not expressed in 
one third (9/27) of study SCC specimens (Table 1). 
Eighteen (67%) SCC specimens showed strong 
(+++) GHR positivity (Table 1). Immunoreactive 
keratinocytes were diffusely spread over positive 
SCC lesions. Well-differentiated tumor cells in the 
proximity of keratin pearls showed more intense 





n                        %
Bcl-2
n                        %
GHR
n                   %
- 3 11 9 33 2 7
+ 8 30 17 63 2 7
++ 11 41 1 4 5 19
+++ 5 18 0 0 18 67
Total positive 24 89 18 67 25 93
Table 1. Expression of TP53, Bcl-2 and growth hormone receptor (GHR) in squamous cell carcinoma of 
the skin (N=27)
-, no positive cells; +, less than 10% of positive cells; ++, 10%-25% of positive cells;  
+++, more than 25% of positive cells
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Figure 1. Representative immunohistochemical staining of perilesional skin (PS) (A) and squamous cell 
carcinoma (SCC) (B) for TP53 protein (MSIP, x400); PS (C) and SCC (D) for Bcl-2 protein (MSIP, x400); 
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 A significantly increased TP53 and GHR and 
decreased Bcl-2 positivity was observed in SCC 
compared with perilesional skin (χ2-test, p<0.05). 
 
DISCUSSION
 Our study revealed TP53, Bcl-2 and GHR im-
munoreactivity of the perilesional skin layers and 
adnexal structures to show a similar pattern as 
previously reported (5,6,8-22). Recent investiga-
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tions of TP53 and Bcl-2 expression in AK as an 
SCC precursor and SCC have associated their 
biological behavior with increased cell proliferation 
rather than protection from apoptosis (5,6). 
 Twenty-four of 27 (89%) SCC specimens in-
vestigated were immunopositive for TP53 protein, 
which is among the highest reported percentage 
of SCC lesions expressing TP53 (5,6,8-14). Only 
Nelson et al. (9) detected a higher percentage 
of TP53 expression: 12 of 13 (92%) SCC inves-
tigated. Most studies observed TP53 immuno-
reactivity in approximately half of SCC samples 
(10,11,13,14), which is similar to the proportion 
of SCC specimens showing stronger TP53 immu-
nopositivity than perilesional skin (++/+++) detect-
ed in our study, i.e. 59% (16/27).
 Antiapoptotic protein Bcl-2 was weakly (+) 
positive in 67% of SCC specimens investigated, 
similar to the report by Tucci et al. (5). Most of 
earlier studies failed to detect Bcl-2 immunoposi-
tivity in SCC samples investigated (16-18). This 
difference could be explained by several reasons. 
Although a small number of specimens and vari-
ous immunohistochemistry techniques should be 
mentioned (5,6,15-18), we consider uniform sam-
pling of material (according to tumor grade, lesion 
location, patient sex and age) most important. 
 Results of decreased Bcl-2 expression and 
TP53 overexpression in SCC might indicate a 
relatively low importance of protection from apop-
tosis in SCC development and progression. This 
finding is supported by the work of Rossiter et 
al. (23), who found Bcl-2 overexpression to have 
a suppressive role in the development and pro-
gression of SCC. However, TP53 overexpression 
might provide explanation for decreased Bcl-2 
expression: it indicates Tp53 mutation, and mu-
tated form of TP53 cannot initiate bax transcrip-
tion (TP53 regulates transcriptionally the quantity 
of pro-apoptotic protein Bax (24)). Anti-apoptotic 
protein Bcl-2 interacts with Bax and in this way 
blocks apoptosis induced by Bax (25). Thus, even 
decreased Bcl-2 expression can protect cell with 
mutated Tp53 from apoptosis. This hypothesis 
needs to be confirmed by further investigations.
 On the other hand, cell proliferation is con-
nected with increased responsiveness to growth 
factors such as growth hormone. Our finding 
of GHR immunoreactivty in the majority of SCC 
specimens investigated (93%), similar to a previ-
ous report (20), supports the opinion that GHR is 
an ubiquitous receptor in proliferative cutaneous 
lesions (19,20). 
 Furthermore, our two previous studies detected 
moderate to strong (++/+++) GHR expression in 8 
of 36 (24%) HAK and 8 of 25 (32%) AAK speci-
mens (21,22). As the current study found moder-
ate to strong GHR expression in 23 of 27 (86%) 
SCC specimens, this might suggest that those 
AK with increased GHR expression have a higher 
proliferative potential and may be progressing to 
SCC. These findings implicate the role of growth 
hormone and cell proliferation in the development 
of different kinds of cutaneous precancerous le-
sions (AK) and neoplasms (SCC).
 In conclusion, our results generally agree 
with the hypothesis that increased cell prolifera-
tion has an important role in the biological be-
havior of SCC. However, the role of protection 
from apoptosis, especially through detecting Bax 
immunopositivity, should be further evaluated. 
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